FindTrial
Sign In

Long-term clinical outcome of chronic hepatitis B naive patients treated with entecavir and tenofovir in Korea

Long-term clinical outcome of chronic hepatitis B naive patients treated with entecavir and tenofovir in Korea

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008111
Enrollment
2000
Registered
2023-01-13
Start date
2021-04-15
Completion date
Unknown
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Hallym University Medical Center-Dongtan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who were prescribed entecavir as an initial treatment for chronic hepatitis B between January 2011 and January 2014 Patients who were prescribed tenofovir as an initial treatment for chronic hepatitis B between December 2012 and December 2015

Exclusion criteria

Exclusion criteria: Patients who could not be followed up within 1 year after administration of entecavir or tenofovir Patients diagnosed with liver cancer before and within 1 year after administration of entecavir or tenofovir Patients diagnosed with other types of malignancies during the 5 years prior to administration of entecavir or tenofovir Patients co-infected with HCV or HIV

Design outcomes

Primary

MeasureTime frame
HCC development—

Secondary

MeasureTime frame
mortality, liver-related mortality, and other carcinoma incidence—

Countries

Korea, Republic of

Contacts

Public ContactJanghan Jung

Hallym University Medical Center-Dongtan

jhjung0410@gmail.com+82-31-8086-2854

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026